Optimization of NIBS for Treatment of Addiction
Key facts
- Who runs it
- Case Western Reserve University
- Where
- Cambridge, Cleveland, and Hinsdale, United StatesSee the 3 sites
- Trial code
- Status
- Recruiting
- People taking part
- 126 people, planned
- Started
- 4 Apr 2021
- Expected to end
- 31 Oct 2027
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Active Comparator: Active tDCS + Active TUS
- Sham Comparator: Sham tDCS + Sham TUS
- Record updated
- 4 March 2026
Who can take part
- Age
- 18 years to 85 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Participants must meet all of the following:
- Provide informed consent
- Age 18-85 years
- Diagnosis of opioid use disorder (DSM-5) with ongoing non-prescription opioid use confirmed by self-report and urine toxicology
- Report current opioid craving
- Enrolled in a certified Opioid Treatment Program and receiving methadone maintenance treatment
- Stable methadone dose prior to enrollment
- Reside locally with no plans to relocate during the study Exclusion Criteria; Participants will be excluded if they:
- Are pregnant
- Have frequent illicit stimulant use or acute stimulant intoxication
- Are using substances or medications that may interfere with study assessments (e.g., stimulant medications, buprenorphine-based therapies, naltrexone)
- Have significant neurological conditions (e.g., stroke, epilepsy, brain tumor), abnormal EEG findings, history of brain surgery, significant head injury, or unexplained syncope
- Have contraindications to noninvasive brain stimulation (e.g., metal in the head, implanted brain devices)
- Have moderate to severe depression or active suicidal ideation/behavior
- Have active malignancy
- Consume substances that could confound opioid toxicology results (e.g., poppy-seed products)
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Where in United States
- Spaulding Rehabilitation Hospital - 5th Floor - Neuromodulation CenterCambridge, United StatesContact: Elly Pichardo, MDTaking people
- University Hospitals Cleveland Medical Center/ Dahms Clinical Research UnitCleveland, United StatesContact: Salim Hayek, MDTaking people
- University of Illinois Health/ University of Illinois at ChicagoHinsdale, United StatesContact: Ming-Chieh Shun, PhDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to assess the effects of transcranial Direct Current Stimulation (tDCS) applied in conjunction with Transcranial Ultrasound (TUS) for the treatment of addiction in opiate use disorder with chronic pain. The investigators hypothesize that there will be a decrease in drug use and improved psychosocial assessments with active stimulation, when compared to sham stimulation.
The 2 groups in the trial
- Active (tDCS) + Active TUSExisting treatment, for comparison
Subjects in the experimental group will undergo 20 minutes of active transcranial direct current stimulation (tDCS) and active transcranial ultrasound (TUS)
Treatment: Active Comparator: Active tDCS + Active TUS
- Sham (tDCS) + Sham TUSSham treatment, for comparison
Subjects in the sham group will undergo 20 minutes of sham transcranial direct current stimulation (tDCS) and sham transcranial ultrasound (TUS).
Treatment: Sham Comparator: Sham tDCS + Sham TUS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Optimization of Non-Invasive Brain Stimulation for Treatment of Addiction
- Fit questions
- Built from NCT04379115, who can take part
- Record updated
- 4 March 2026